Anusha Vallurupalli, MD
Hematology · Portland, ORNPI 1700107745
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $4,039 of the $4,622 with a category attached, or 87.4%. Gilead accounts for 90.4% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $2,288 and has fallen 97.0% since, to $68 in 2025.
Across 15 payments — averaging $308.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$4K
- F. Hoffmann-la Roche AG$346
- AstraZeneca$68
- Acrotech Biopharma Inc.$28
Across 175 payments — averaging $6893.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pharmacyclics LLC, An Abbvie Company$255K
- Genentech, Inc.$232K
- Genmab U.S., Inc.$232K
- Acerta Pharma LLC$145K
- AbbVie$101K
- Amgen$64K
- plus $176K from 6 others
What the payments were for
- Speaking & faculty fees$3467%
- Travel & lodging$4,03987%
- Food & beverage$1403%
- Education$962%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 10 | $4,180 |
| F. Hoffmann-la Roche AG | 2 | $346 |
| AstraZeneca | 1 | $68 |
| Acrotech Biopharma Inc. | 2 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yescarta$4,039
- Non-Covered Product$346
How this compares
$4,622 in reported general payments places this provider in the 65th percentile of 27 hematology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 14 | $223,383 |
| IbrancePalbociclib | 12 | $181,560 |
| Lenalidomide | 11 | $167,686 |
| EliquisApixaban | 50 | $36,881 |
| XareltoRivaroxaban | 17 | $18,018 |
| ValacyclovirValacyclovir Hcl | 29 | $1,162 |
| Letrozole | 39 | $1,091 |
| Ondansetron Hcl | 33 | $880 |
| Anastrozole | 53 | $771 |
| Dexamethasone | 79 | $478 |
| Prochlorperazine Maleate | 47 | $313 |
| Tamoxifen Citrate | 14 | $204 |
| Ondansetron OdtOndansetron | 14 | $183 |
| Megestrol Acetate | 16 | $181 |
| Gabapentin | 12 | $53 |
Paid to pharmacies, not to this prescriber.
Other hematology in Portland
- John GodwinPortland$52K
- Rebecca SilbermannPortland$26K
- Jessica LeonardPortland$26K
- Ronan SwordsPortland$11K
- Andy ChenPortland$11K
- Hugo AkabanePortland$11K
- Guang FanPortland$7K
- Rachel CookPortland$7K
- Elizabeth MillerPortland$3K
- Emma ScottPortland$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.